Insmed Inc is a biopharmaceutical firm focused on developing and marketing treatments for patients with serious and rare diseases globally. Its flagship product, ARIKAYCE, targets Mycobacterium avium complex lung disease in adults. The company is also working on Brensocatib for bronchiectasis and other diseases, and Treprostinil Palmitil Inhalation Powder for certain types of pulmonary hypertension. Founded in 1988, Insmed is based in Bridgewater, New Jersey, serving patients in the US, Europe, Japan, and beyond.
Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find…
Stanley Druckenmiller is skipping the mega-cap tech herd and loading up on a Mexican discount grocer, an Argentine shale producer, and a biotech that Wall Street just handed a 38% discount despite…
Billionaire investor Stanley Druckenmiller is known for making bold moves when conviction is high, and his latest portfolio changes suggest he sees a major opportunity developing in one corner of the market.…
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on…
Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM | INSM Price Prediction) and its lung disease franchise: Japan has more patients with MAC lung disease than the…
Pre-Market Stock Futures: Futures are trading lower as we prepare to wrap up a rollercoaster week marked by huge market swings. Still, ultimately, President Trump’s TACO (Trump Always Chickens Out) move on…
Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning. He has been piling into Natera (NASDAQ:NTRA | NTRA Price Prediction),…
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing. He’s now piling into Natera (NASDAQ:NTRA | NTRA Price…
Thursday's top analyst upgrades and downgrades included Alphabet, Eli Lilly, Etsy, Microsoft, Mosaic, NetApp, Omega Healthcare Investors, RTX, Sherwin-Williams, Spotify Technology, Walt Disney and WW International.
Thursday's top analyst upgrades and downgrades included Airbnb, Applied Materials, AutoZone, BorgWarner, Carvana, Dominion Energy, EQT, MongoDB, NRG Energy, PagSeguro Digital, Southwestern Energy, Stitch Fix, StoneCo and TripAdvisor.
Wednesday's top analyst upgrades and downgrades included Albemarle, Camping World, eBay, EOG Resources, Etsy, Global Payments, IMAX, JPMorgan Chase, MetLife, Otis Worldwide, Salesforce, Wayfair and Zillow.
Thursday's top analyst upgrades and downgrades included Alphabet, Allstate, Antero Midstream, Archer Daniels Midland, Capital One Financial, Chipotle Mexican Grill, Corning, Microsoft, PepsiCo, QuantumScape, Range Resources, Spotify Technology, Texas Instruments, Visa and…
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic…
